Search This Blog

Wednesday, May 13, 2026

Arbutus: Moderna settlement, fast track for hep B

 

Arbutus Biopharma reports Q1 net income of $169.7M ($0.87 per share) on $179.1M revenue driven by Moderna settlement

  • Arbutus Biopharma receives FDA Fast Track designation for its hepatitis B drug imdusiran.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)